Global Patient derived Xenograft (PDX) Models Market Research Report 2022(Status and Outlook)

June 2022 | 122 pages | ID: G8573FF570A4EN
Bosson Research

Abstracts

Report Overview

The Global Patient derived Xenograft (PDX) Models Market Size was estimated at USD 331.96 million in 2021 and is projected to reach USD 590.85 million by 2028, exhibiting a CAGR of 8.59% during the forecast period.

Bosson Research’s latest report provides a deep insight into the global Patient derived Xenograft (PDX) Models market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Patient derived Xenograft (PDX) Models Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Patient derived Xenograft (PDX) Models market in any manner.

Global Patient derived Xenograft (PDX) Models Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

• Crown Bioscience
• Champions Oncology
• Wuxi Apptec
• The Jackson Laboratory
• EPO Berlin-Buch
• Oncodesign
• Xentech
• Envigo
• Charles River Laboratories
• Pharmatest Services
• Urosphere
• MEDICILON
• Horizon Discovery
• Shanghai Model Organisms Center
• GemPharmatech
• LIDE Biotech

Market Segmentation (by Type)

• Mouse Model
• Rat Model
• Patient-derived Xenograft (PDX)

Market Segmentation (by Application)

• Preclinical Drug development
• Biomarker Analysis

Geographic Segmentation

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Patient derived Xenograft (PDX) Models Market
• Overview of the regional outlook of the Patient derived Xenograft (PDX) Models Market:

Key Reasons to Buy this Report:

• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Note: this report may need to undergo a final check or review and this could take about 48 hours.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Patient derived Xenograft (PDX) Models Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Patient derived Xenograft (PDX) Models
1.2 Key Market Segments
  1.2.1 Patient derived Xenograft (PDX) Models Segment by Type
  1.2.2 Patient derived Xenograft (PDX) Models Segment by Application
1.3 Methodology & Sources of Information
  1.3.1 Research Methodology
  1.3.2 Research Process
  1.3.3 Market Breakdown and Data Triangulation
  1.3.4 Base Year
  1.3.5 Report Assumptions & Caveats

2 PATIENT DERIVED XENOGRAFT (PDX) MODELS MARKET OVERVIEW

2.1 Global Patient derived Xenograft (PDX) Models Market Size (M USD) Estimates and Forecasts (2017-2028)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region

3 PATIENT DERIVED XENOGRAFT (PDX) MODELS MARKET COMPETITIVE LANDSCAPE

3.1 Global Patient derived Xenograft (PDX) Models Revenue Market Share by Manufacturers (2017-2022)
3.2 Patient derived Xenograft (PDX) Models Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturers Patient derived Xenograft (PDX) Models Sales Sites, Area Served, Service Type
3.4 Patient derived Xenograft (PDX) Models Market Competitive Situation and Trends
  3.4.1 Patient derived Xenograft (PDX) Models Market Concentration Rate
  3.4.2 Global 5 and 10 Largest Patient derived Xenograft (PDX) Models Players Market Share by Revenue
  3.4.3 Mergers & Acquisitions, Expansion

4 PATIENT DERIVED XENOGRAFT (PDX) MODELS VALUE CHAIN ANALYSIS

4.1 Patient derived Xenograft (PDX) Models Value Chain Analysis
4.2 Midstream Market Analysis
4.3 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF PATIENT DERIVED XENOGRAFT (PDX) MODELS MARKET

5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
  5.5.1 Mergers & Acquisitions
  5.5.2 Expansions
  5.5.3 Collaboration/Supply Contracts
5.6 Industry Policies

6 PATIENT DERIVED XENOGRAFT (PDX) MODELS MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Patient derived Xenograft (PDX) Models Market Size Market Share by Type (2017-2022)
6.3 Global Patient derived Xenograft (PDX) Models Sales Growth Rate by Type (2017-2022)

7 PATIENT DERIVED XENOGRAFT (PDX) MODELS MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Patient derived Xenograft (PDX) Models Market Size (M USD) by Application (2017-2022)
7.3 Global Patient derived Xenograft (PDX) Models Sales Growth Rate by Application (2017-2022)

8 PATIENT DERIVED XENOGRAFT (PDX) MODELS MARKET SEGMENTATION BY REGION

8.1 Global Patient derived Xenograft (PDX) Models Market Size by Region
  8.1.1 Global Patient derived Xenograft (PDX) Models Market Size by Region
  8.1.2 Global Patient derived Xenograft (PDX) Models Market Share by Region
8.2 North America
  8.2.1 North America Patient derived Xenograft (PDX) Models Market Size by Country
  8.2.2 U.S.
  8.2.3 Canada
  8.2.4 Mexico
8.3 Europe
  8.3.1 Europe Patient derived Xenograft (PDX) Models Market Size by Country
  8.3.2 Germany
  8.3.3 France
  8.3.4 U.K.
  8.3.5 Italy
  8.3.6 Russia
8.4 Asia Pacific
  8.4.1 Asia Pacific Patient derived Xenograft (PDX) Models Market Size by Region
  8.4.2 China
  8.4.3 Japan
  8.4.4 South Korea
  8.4.5 India
  8.4.6 Southeast Asia
8.5 South America
  8.5.1 South America Patient derived Xenograft (PDX) Models Market Size by Country
  8.5.2 Brazil
  8.5.3 Argentina
  8.5.4 Columbia
8.6 Middle East and Africa
  8.6.1 Middle East and Africa Patient derived Xenograft (PDX) Models Market Size by Region
  8.6.2 Saudi Arabia
  8.6.3 UAE
  8.6.4 Egypt
  8.6.5 Nigeria
  8.6.6 South Africa

9 KEY COMPANIES PROFILED

9.1 Crown Bioscience
  9.1.1 Crown Bioscience Patient derived Xenograft (PDX) Models Basic Information
  9.1.2 Crown Bioscience Patient derived Xenograft (PDX) Models Product Overview
  9.1.3 Crown Bioscience Patient derived Xenograft (PDX) Models Product Market Performance
  9.1.4 Crown Bioscience Business Overview
  9.1.5 Crown Bioscience Patient derived Xenograft (PDX) Models SWOT Analysis
  9.1.6 Crown Bioscience Recent Developments
9.2 Champions Oncology
  9.2.1 Champions Oncology Patient derived Xenograft (PDX) Models Basic Information
  9.2.2 Champions Oncology Patient derived Xenograft (PDX) Models Product Overview
  9.2.3 Champions Oncology Patient derived Xenograft (PDX) Models Product Market Performance
  9.2.4 Champions Oncology Business Overview
  9.2.5 Champions Oncology Patient derived Xenograft (PDX) Models SWOT Analysis
  9.2.6 Champions Oncology Recent Developments
9.3 Wuxi Apptec
  9.3.1 Wuxi Apptec Patient derived Xenograft (PDX) Models Basic Information
  9.3.2 Wuxi Apptec Patient derived Xenograft (PDX) Models Product Overview
  9.3.3 Wuxi Apptec Patient derived Xenograft (PDX) Models Product Market Performance
  9.3.4 Wuxi Apptec Business Overview
  9.3.5 Wuxi Apptec Patient derived Xenograft (PDX) Models SWOT Analysis
  9.3.6 Wuxi Apptec Recent Developments
9.4 The Jackson Laboratory
  9.4.1 The Jackson Laboratory Patient derived Xenograft (PDX) Models Basic Information
  9.4.2 The Jackson Laboratory Patient derived Xenograft (PDX) Models Product Overview
  9.4.3 The Jackson Laboratory Patient derived Xenograft (PDX) Models Product Market Performance
  9.4.4 The Jackson Laboratory Business Overview
  9.4.5 The Jackson Laboratory Patient derived Xenograft (PDX) Models SWOT Analysis
  9.4.6 The Jackson Laboratory Recent Developments
9.5 EPO Berlin-Buch
  9.5.1 EPO Berlin-Buch Patient derived Xenograft (PDX) Models Basic Information
  9.5.2 EPO Berlin-Buch Patient derived Xenograft (PDX) Models Product Overview
  9.5.3 EPO Berlin-Buch Patient derived Xenograft (PDX) Models Product Market Performance
  9.5.4 EPO Berlin-Buch Business Overview
  9.5.5 EPO Berlin-Buch Patient derived Xenograft (PDX) Models SWOT Analysis
  9.5.6 EPO Berlin-Buch Recent Developments
9.6 Oncodesign
  9.6.1 Oncodesign Patient derived Xenograft (PDX) Models Basic Information
  9.6.2 Oncodesign Patient derived Xenograft (PDX) Models Product Overview
  9.6.3 Oncodesign Patient derived Xenograft (PDX) Models Product Market Performance
  9.6.4 Oncodesign Business Overview
  9.6.5 Oncodesign Recent Developments
9.7 Xentech
  9.7.1 Xentech Patient derived Xenograft (PDX) Models Basic Information
  9.7.2 Xentech Patient derived Xenograft (PDX) Models Product Overview
  9.7.3 Xentech Patient derived Xenograft (PDX) Models Product Market Performance
  9.7.4 Xentech Business Overview
  9.7.5 Xentech Recent Developments
9.8 Envigo
  9.8.1 Envigo Patient derived Xenograft (PDX) Models Basic Information
  9.8.2 Envigo Patient derived Xenograft (PDX) Models Product Overview
  9.8.3 Envigo Patient derived Xenograft (PDX) Models Product Market Performance
  9.8.4 Envigo Business Overview
  9.8.5 Envigo Recent Developments
9.9 Charles River Laboratories
  9.9.1 Charles River Laboratories Patient derived Xenograft (PDX) Models Basic Information
  9.9.2 Charles River Laboratories Patient derived Xenograft (PDX) Models Product Overview
  9.9.3 Charles River Laboratories Patient derived Xenograft (PDX) Models Product Market Performance
  9.9.4 Charles River Laboratories Business Overview
  9.9.5 Charles River Laboratories Recent Developments
9.10 Pharmatest Services
  9.10.1 Pharmatest Services Patient derived Xenograft (PDX) Models Basic Information
  9.10.2 Pharmatest Services Patient derived Xenograft (PDX) Models Product Overview
  9.10.3 Pharmatest Services Patient derived Xenograft (PDX) Models Product Market Performance
  9.10.4 Pharmatest Services Business Overview
  9.10.5 Pharmatest Services Recent Developments
9.11 Urosphere
  9.11.1 Urosphere Patient derived Xenograft (PDX) Models Basic Information
  9.11.2 Urosphere Patient derived Xenograft (PDX) Models Product Overview
  9.11.3 Urosphere Patient derived Xenograft (PDX) Models Product Market Performance
  9.11.4 Urosphere Business Overview
  9.11.5 Urosphere Recent Developments
9.12 MEDICILON
  9.12.1 MEDICILON Patient derived Xenograft (PDX) Models Basic Information
  9.12.2 MEDICILON Patient derived Xenograft (PDX) Models Product Overview
  9.12.3 MEDICILON Patient derived Xenograft (PDX) Models Product Market Performance
  9.12.4 MEDICILON Business Overview
  9.12.5 MEDICILON Recent Developments
9.13 Horizon Discovery
  9.13.1 Horizon Discovery Patient derived Xenograft (PDX) Models Basic Information
  9.13.2 Horizon Discovery Patient derived Xenograft (PDX) Models Product Overview
  9.13.3 Horizon Discovery Patient derived Xenograft (PDX) Models Product Market Performance
  9.13.4 Horizon Discovery Business Overview
  9.13.5 Horizon Discovery Recent Developments
9.14 Shanghai Model Organisms Center
  9.14.1 Shanghai Model Organisms Center Patient derived Xenograft (PDX) Models Basic Information
  9.14.2 Shanghai Model Organisms Center Patient derived Xenograft (PDX) Models Product Overview
  9.14.3 Shanghai Model Organisms Center Patient derived Xenograft (PDX) Models Product Market Performance
  9.14.4 Shanghai Model Organisms Center Business Overview
  9.14.5 Shanghai Model Organisms Center Recent Developments
9.15 GemPharmatech
  9.15.1 GemPharmatech Patient derived Xenograft (PDX) Models Basic Information
  9.15.2 GemPharmatech Patient derived Xenograft (PDX) Models Product Overview
  9.15.3 GemPharmatech Patient derived Xenograft (PDX) Models Product Market Performance
  9.15.4 GemPharmatech Business Overview
  9.15.5 GemPharmatech Recent Developments
9.16 LIDE Biotech
  9.16.1 LIDE Biotech Patient derived Xenograft (PDX) Models Basic Information
  9.16.2 LIDE Biotech Patient derived Xenograft (PDX) Models Product Overview
  9.16.3 LIDE Biotech Patient derived Xenograft (PDX) Models Product Market Performance
  9.16.4 LIDE Biotech Business Overview
  9.16.5 LIDE Biotech Recent Developments

10 PATIENT DERIVED XENOGRAFT (PDX) MODELS REGIONAL MARKET FORECAST

10.1 Global Patient derived Xenograft (PDX) Models Market Size Forecast
10.2 Global Patient derived Xenograft (PDX) Models Market Forecast by Region
  10.2.1 North America Market Size Forecast by Country
  10.2.2 Europe Patient derived Xenograft (PDX) Models Market Size Forecast by Country
  10.2.3 Asia Pacific Patient derived Xenograft (PDX) Models Market Size Forecast by Region
  10.2.4 South America Patient derived Xenograft (PDX) Models Market Size Forecast by Country
  10.2.5 Middle East and Africa Forecasted Consumption of Patient derived Xenograft (PDX) Models by Country

11 MARKET SEGMENTATION & SIZE FORECAST (2023-2028)

11.1 Global Patient derived Xenograft (PDX) Models Market Forecast by Type (2023-2028)
11.2 Global Patient derived Xenograft (PDX) Models Market Forecast by Application (2023-2028)

12 CONCLUSION AND KEY FINDINGSLIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Patient derived Xenograft (PDX) Models Market Size (M USD) Comparison by Region (M USD)
Table 5. Global Patient derived Xenograft (PDX) Models Revenue (M USD) by Manufacturers (2017-2022)
Table 6. Global Patient derived Xenograft (PDX) Models Revenue Share by Manufacturers (2017-2022)
Table 7. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Patient derived Xenograft (PDX) Models as of 2021)
Table 8. Manufacturers Patient derived Xenograft (PDX) Models Sales Sites and Area Served
Table 9. Manufacturers Patient derived Xenograft (PDX) Models Service Type
Table 10. Global Patient derived Xenograft (PDX) Models Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. Value Chain Map of Patient derived Xenograft (PDX) Models
Table 13. Midstream Market Analysis
Table 14. Downstream Customer Analysis
Table 15. Key Development Trends
Table 16. Driving Factors
Table 17. Patient derived Xenograft (PDX) Models Market Challenges
Table 18. Market Restraints
Table 19. Global Patient derived Xenograft (PDX) Models Market Size by Type (M USD)
Table 20. Global Patient derived Xenograft (PDX) Models Market Size (M USD) by Type (2017-2022)
Table 21. Global Patient derived Xenograft (PDX) Models Market Size Share by Type (2017-2022)
Table 22. Global Patient derived Xenograft (PDX) Models Sales Growth Rate by Type (2017-2022)
Table 23. Global Patient derived Xenograft (PDX) Models Sales (K Units) by Application
Table 24. Global Patient derived Xenograft (PDX) Models Market Size by Application
Table 25. Global Patient derived Xenograft (PDX) Models Sales by Application (2017-2022) & (M USD)
Table 26. Global Patient derived Xenograft (PDX) Models Market Share by Application (2017-2022)
Table 27. Global Patient derived Xenograft (PDX) Models Sales Growth Rate by Application (2017-2022)
Table 28. Global Patient derived Xenograft (PDX) Models Market Size by Region (2017-2022) & (M USD)
Table 29. Global Patient derived Xenograft (PDX) Models Market Share by Region (2017-2022)
Table 30. North America Patient derived Xenograft (PDX) Models Market Size by Country (2017-2022) & (M USD)
Table 31. Europe Patient derived Xenograft (PDX) Models Market Size by Country (2017-2022) & (M USD)
Table 32. Asia Pacific Patient derived Xenograft (PDX) Models Market Size by Region (2017-2022) & (M USD)
Table 33. South America Patient derived Xenograft (PDX) Models Market Size by Country (2017-2022) & (M USD)
Table 34. Middle East and Africa Patient derived Xenograft (PDX) Models Market Size by Region (2017-2022) & (M USD)
Table 35. Crown Bioscience Patient derived Xenograft (PDX) Models Basic Information
Table 36. Crown Bioscience Patient derived Xenograft (PDX) Models Product Overview
Table 37. Crown Bioscience Patient derived Xenograft (PDX) Models Revenue (M USD) and Gross Margin (2017-2022)
Table 38. Crown Bioscience Business Overview
Table 39. Crown Bioscience Patient derived Xenograft (PDX) Models SWOT Analysis
Table 40. Crown Bioscience Recent Developments
Table 41. Champions Oncology Patient derived Xenograft (PDX) Models Basic Information
Table 42. Champions Oncology Patient derived Xenograft (PDX) Models Product Overview
Table 43. Champions Oncology Patient derived Xenograft (PDX) Models Revenue (M USD) and Gross Margin (2017-2022)
Table 44. Champions Oncology Business Overview
Table 45. Champions Oncology Patient derived Xenograft (PDX) Models SWOT Analysis
Table 46. Champions Oncology Recent Developments
Table 47. Wuxi Apptec Patient derived Xenograft (PDX) Models Basic Information
Table 48. Wuxi Apptec Patient derived Xenograft (PDX) Models Product Overview
Table 49. Wuxi Apptec Patient derived Xenograft (PDX) Models Revenue (M USD) and Gross Margin (2017-2022)
Table 50. Wuxi Apptec Business Overview
Table 51. Wuxi Apptec Patient derived Xenograft (PDX) Models SWOT Analysis
Table 52. Wuxi Apptec Recent Developments
Table 53. The Jackson Laboratory Patient derived Xenograft (PDX) Models Basic Information
Table 54. The Jackson Laboratory Patient derived Xenograft (PDX) Models Product Overview
Table 55. The Jackson Laboratory Patient derived Xenograft (PDX) Models Revenue (M USD) and Gross Margin (2017-2022)
Table 56. The Jackson Laboratory Business Overview
Table 57. The Jackson Laboratory Patient derived Xenograft (PDX) Models SWOT Analysis
Table 58. The Jackson Laboratory Recent Developments
Table 59. EPO Berlin-Buch Patient derived Xenograft (PDX) Models Basic Information
Table 60. EPO Berlin-Buch Patient derived Xenograft (PDX) Models Product Overview
Table 61. EPO Berlin-Buch Patient derived Xenograft (PDX) Models Revenue (M USD) and Gross Margin (2017-2022)
Table 62. EPO Berlin-Buch Business Overview
Table 63. EPO Berlin-Buch Patient derived Xenograft (PDX) Models SWOT Analysis
Table 64. EPO Berlin-Buch Recent Developments
Table 65. Oncodesign Patient derived Xenograft (PDX) Models Basic Information
Table 66. Oncodesign Patient derived Xenograft (PDX) Models Product Overview
Table 67. Oncodesign Patient derived Xenograft (PDX) Models Revenue (M USD) and Gross Margin (2017-2022)
Table 68. Oncodesign Business Overview
Table 69. Oncodesign Recent Developments
Table 70. Xentech Patient derived Xenograft (PDX) Models Basic Information
Table 71. Xentech Patient derived Xenograft (PDX) Models Product Overview
Table 72. Xentech Patient derived Xenograft (PDX) Models Revenue (M USD) and Gross Margin (2017-2022)
Table 73. Xentech Business Overview
Table 74. Xentech Recent Developments
Table 75. Envigo Patient derived Xenograft (PDX) Models Basic Information
Table 76. Envigo Patient derived Xenograft (PDX) Models Product Overview
Table 77. Envigo Patient derived Xenograft (PDX) Models Revenue (M USD) and Gross Margin (2017-2022)
Table 78. Envigo Business Overview
Table 79. Envigo Recent Developments
Table 80. Charles River Laboratories Patient derived Xenograft (PDX) Models Basic Information
Table 81. Charles River Laboratories Patient derived Xenograft (PDX) Models Product Overview
Table 82. Charles River Laboratories Patient derived Xenograft (PDX) Models Revenue (M USD) and Gross Margin (2017-2022)
Table 83. Charles River Laboratories Business Overview
Table 84. Charles River Laboratories Recent Developments
Table 85. Pharmatest Services Patient derived Xenograft (PDX) Models Basic Information
Table 86. Pharmatest Services Patient derived Xenograft (PDX) Models Product Overview
Table 87. Pharmatest Services Patient derived Xenograft (PDX) Models Revenue (M USD) and Gross Margin (2017-2022)
Table 88. Pharmatest Services Business Overview
Table 89. Pharmatest Services Recent Developments
Table 90. Urosphere Patient derived Xenograft (PDX) Models Basic Information
Table 91. Urosphere Patient derived Xenograft (PDX) Models Product Overview
Table 92. Urosphere Patient derived Xenograft (PDX) Models Revenue (M USD) and Gross Margin (2017-2022)
Table 93. Urosphere Business Overview
Table 94. Urosphere Recent Developments
Table 95. MEDICILON Patient derived Xenograft (PDX) Models Basic Information
Table 96. MEDICILON Patient derived Xenograft (PDX) Models Product Overview
Table 97. MEDICILON Patient derived Xenograft (PDX) Models Revenue (M USD) and Gross Margin (2017-2022)
Table 98. MEDICILON Business Overview
Table 99. MEDICILON Recent Developments
Table 100. Horizon Discovery Patient derived Xenograft (PDX) Models Basic Information
Table 101. Horizon Discovery Patient derived Xenograft (PDX) Models Product Overview
Table 102. Horizon Discovery Patient derived Xenograft (PDX) Models Revenue (M USD) and Gross Margin (2017-2022)
Table 103. Horizon Discovery Business Overview
Table 104. Horizon Discovery Recent Developments
Table 105. Shanghai Model Organisms Center Patient derived Xenograft (PDX) Models Basic Information
Table 106. Shanghai Model Organisms Center Patient derived Xenograft (PDX) Models Product Overview
Table 107. Shanghai Model Organisms Center Patient derived Xenograft (PDX) Models Revenue (M USD) and Gross Margin (2017-2022)
Table 108. Shanghai Model Organisms Center Business Overview
Table 109. Shanghai Model Organisms Center Recent Developments
Table 110. GemPharmatech Patient derived Xenograft (PDX) Models Basic Information
Table 111. GemPharmatech Patient derived Xenograft (PDX) Models Product Overview
Table 112. GemPharmatech Patient derived Xenograft (PDX) Models Revenue (M USD) and Gross Margin (2017-2022)
Table 113. GemPharmatech Business Overview
Table 114. GemPharmatech Recent Developments
Table 115. LIDE Biotech Patient derived Xenograft (PDX) Models Basic Information
Table 116. LIDE Biotech Patient derived Xenograft (PDX) Models Product Overview
Table 117. LIDE Biotech Patient derived Xenograft (PDX) Models Revenue (M USD) and Gross Margin (2017-2022)
Table 118. LIDE Biotech Business Overview
Table 119. LIDE Biotech Recent Developments
Table 120. Global Patient derived Xenograft (PDX) Models Market Size Forecast by Region (M USD)
Table 121. North America Patient derived Xenograft (PDX) Models Market Size Forecast by Country (2023-2028) & (M USD)
Table 122. Europe Patient derived Xenograft (PDX) Models Market Size Forecast by Country (2023-2028) & (M USD)
Table 123. Asia Pacific Patient derived Xenograft (PDX) Models Market Size Forecast by Region (2023-2028) & (M USD)
Table 124. South America Patient derived Xenograft (PDX) Models Market Size Forecast by Country (2023-2028) & (M
USD)
Table 125. Middle East and Africa Patient derived Xenograft (PDX) Models Market Size Forecast by Country (2023-2028) & (M USD)
Table 126. Global Patient derived Xenograft (PDX) Models Market Size Forecast by Type (2023-2028) & (M USD)
Table 127. Global Patient derived Xenograft (PDX) Models Market Size Forecast by Application (2023-2028) & (M USD)
LIST OF FIGURES
Figure 1. Industrial Chain of Patient derived Xenograft (PDX) Models
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Patient derived Xenograft (PDX) Models Market Size (M USD), 2017-2028
Figure 5. Global Patient derived Xenograft (PDX) Models Market Size (M USD) (2017-2028)
Figure 6. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 8. Evaluation Matrix of Regional Market Development Potential
Figure 9. Patient derived Xenograft (PDX) Models Market Size (M USD) by Country (M USD)
Figure 10. Global Patient derived Xenograft (PDX) Models Revenue Share by Manufacturers in 2021
Figure 11. Patient derived Xenograft (PDX) Models Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 12. The Global 5 and 10 Largest Players: Market Share by Patient derived Xenograft (PDX) Models Revenue in 2021
Figure 13. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 14. Global Patient derived Xenograft (PDX) Models Market Share by Type
Figure 15. Market Size Share of Patient derived Xenograft (PDX) Models by Type (2017-2022)
Figure 16. Market Size Market Share of Patient derived Xenograft (PDX) Models by Type in 2021
Figure 17. Global Patient derived Xenograft (PDX) Models Sales Growth Rate by Type (2017-2022)
Figure 18. Global Patient derived Xenograft (PDX) Models Market Share by Application
Figure 19. Global Patient derived Xenograft (PDX) Models Market Share by Application (2017-2022)
Figure 20. Global Patient derived Xenograft (PDX) Models Market Share by Application in 2021
Figure 21. Global Patient derived Xenograft (PDX) Models Sales Growth Rate by Application (2017-2022)
Figure 22. Global Patient derived Xenograft (PDX) Models Market Share by Region (2017-2022)
Figure 23. North America Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 24. North America Patient derived Xenograft (PDX) Models Market Share by Country in 2021
Figure 25. U.S. Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 26. Canada Patient derived Xenograft (PDX) Models Market Size (M USD) and Growth Rate (2017-2022)
Figure 27. Mexico Patient derived Xenograft (PDX) Models Market Size (Units) and Growth Rate (2017-2022)
Figure 28. Europe Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 29. Europe Patient derived Xenograft (PDX) Models Market Share by Country in 2021
Figure 30. Germany Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 31. France Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 32. U.K. Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 33. Italy Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 34. Russia Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 35. Asia Pacific Patient derived Xenograft (PDX) Models Market Size and Growth Rate (M USD)
Figure 36. Asia Pacific Patient derived Xenograft (PDX) Models Market Share by Region in 2021
Figure 37. China Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 38. Japan Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 39. South Korea Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 40. India Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 41. Southeast Asia Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 42. South America Patient derived Xenograft (PDX) Models Market Size and Growth Rate (M USD)
Figure 43. South America Patient derived Xenograft (PDX) Models Market Share by Country in 2021
Figure 44. Brazil Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 45. Argentina Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 46. Columbia Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 47. Middle East and Africa Patient derived Xenograft (PDX) Models Market Size and Growth Rate (M USD)
Figure 48. Middle East and Africa Patient derived Xenograft (PDX) Models Market Share by Region in 2021
Figure 49. Saudi Arabia Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 50. UAE Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 51. Egypt Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 52. Nigeria Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 53. South Africa Patient derived Xenograft (PDX) Models Market Size and Growth Rate (2017-2022) & (M USD)
Figure 54. Global Patient derived Xenograft (PDX) Models Market Size Forecast by Value (2017-2028) & (M USD)
Figure 55. Global Patient derived Xenograft (PDX) Models Market Share Forecast by Type (2023-2028)
Figure 56. Global Patient derived Xenograft (PDX) Models Market Share Forecast by Application (2023-2028)